Has Shelby Sanford, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,533 in general payments to Shelby Sanford, MD across 285 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Shelby Sanford, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Shelby Sanford, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Shelby Sanford, MD

Radiation Oncology · Tuscaloosa, ALNPI 1689681967

Payments from drug & device makers

$5,533in general payments, 2019–2025

Across 285 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$725
Daiichi Sankyo Inc.$410
Novartis$392
Johnson & Johnson$372
E.r. Squibb & Sons, L.L.C.$302
Dendreon Pharmaceuticals LLC$239
plus $3K from 51 others

What the payments were for

Food & beverage$5,519100%
Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca(2 entities)	35	$725
Daiichi Sankyo Inc.	19	$410
Novartis	20	$392
Johnson & Johnson	21	$372
E.r. Squibb & Sons, L.L.C.	19	$302
Dendreon Pharmaceuticals LLC	8	$239
Amgen	14	$220
Pfizer	11	$200
Merck	10	$192
AbbVie	7	$148
Incyte Corporation	8	$147
Tersera Therapeutics LLC	5	$125
Pharmaessentia USA Corporation	5	$105
Jazz Pharmaceuticals Inc.	5	$104
Coherus Oncology, Inc.	5	$100
Bayer	6	$100
Seagen Inc.	7	$100
Puma Biotechnology, Inc.	5	$98
Takeda Pharmaceuticals U.S.A., Inc.	4	$95
Octapharma USA, Inc.	4	$81
Eisai Inc.	4	$74
Sanofi	4	$73
Tesaro, Inc.	3	$72
Pharmacyclics LLC, An Abbvie Company	4	$70
EMD Serono, Inc.	3	$70
CSL Behring	2	$67
Astellas Pharma US Inc	3	$59
Tolmar Pharmaceuticals, Inc.	3	$53
Karyopharm Therapeutics Inc.	3	$53
Dova Pharmaceuticals	2	$48
Tempus AI, Inc	2	$46
Genentech USA, Inc.	2	$44
Sobi, Inc	2	$37
Bristol Myers Squibb	2	$35
Agios Pharmaceuticals, Inc.	2	$34
Pharmacosmos Therapeutics Inc.	1	$34
Epizyme, Inc.	2	$33
Sumitomo Pharma America, Inc.	2	$32
Lilly USA, LLC	2	$31
Regeneron Healthcare Solutions, Inc.	2	$27
Spectrum Pharmaceuticals Inc.	1	$26
Blue Earth Diagnostics	1	$22
ADC Therapeutics America, Inc.	1	$21
Servier Pharmaceuticals LLC	1	$20
Fresenius Kabi USA, LLC	1	$19
Genmab U.S., Inc.	1	$19
Recordati_rare_diseases_inc.	1	$19
Stemline Therapeutics Inc.	1	$17
Kyowa Kirin, Inc.	1	$16
Helsinn Therapeutics (U.S.), Inc.	1	$16
Medline Industries LP	1	$15
Myriad Genetic Laboratories, Inc.	1	$14
Taiho Oncology, Inc.	1	$14
Progenics Pharmaceuticals, Inc.	1	$13
Exelixis Inc.	1	$12
Elekta, Inc.	1	$11
Iovance Biotherapeutics, Inc.	1	$10

How this compares

$5,533 in reported general payments places this provider in the 75th percentile of 87 radiation oncology providers in Alabama.

See all radiation oncology providers in Alabama →

Medicare billing

Part B allowed, 2024

$81,123

Medicare patients

Services billed

1,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Levothyroxine Sodium	102	$1,114
Methimazole	22	$301
Tamsulosin Hcl	17	$299

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Tuscaloosa

James TuckerTuscaloosa$6K
John CrewTuscaloosa$4K
Jefferson TruppTuscaloosa$2K
Melanie GrahamTuscaloosa$690
Alexander WhitleyMontgomery$458K
Andrew McDonaldBirmingham$256K
Christopher WilleyBirmingham$213K
Drexell BoggsBirmingham$161K
Samuel MarcromBirmingham$146K
Michael DobelbowerBirmingham$98K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →